Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer

NCT05821686 is registered in ClinicalTrials.gov with Nova Scotia Health Authority as lead sponsor.

NCT NCT05821686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast Cancer
Lead sponsor
Nova Scotia Health Authority
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 2, 2026
Completion date
April 30, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer